Additional investigations concerning the spacer domain of SRPK1 will improve our understanding of tumor progression and help to determine whether SRPK1 represents a viable therapeutic target in gefitinib-resistant NSCLC patients. This evidence concerns the gene SRPK1 and neoplasm.